May Hill Capital LLC acquired a new position in Sanofi (NASDAQ:SNY - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 5,227 shares of the company's stock, valued at approximately $290,000.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Golden State Wealth Management LLC boosted its holdings in Sanofi by 619.3% in the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock worth $35,000 after buying an additional 545 shares during the period. Bessemer Group Inc. boosted its holdings in Sanofi by 59.8% in the 4th quarter. Bessemer Group Inc. now owns 647 shares of the company's stock worth $32,000 after buying an additional 242 shares during the period. Lee Danner & Bass Inc. bought a new position in Sanofi in the 4th quarter worth $31,000. UMB Bank n.a. boosted its holdings in shares of Sanofi by 30.7% during the 1st quarter. UMB Bank n.a. now owns 1,124 shares of the company's stock valued at $62,000 after purchasing an additional 264 shares during the last quarter. Finally, Wayfinding Financial LLC bought a new position in shares of Sanofi during the 1st quarter valued at about $63,000. 14.04% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
SNY has been the subject of several research reports. Hsbc Global Res raised shares of Sanofi to a "strong-buy" rating in a report on Monday, April 28th. Barclays reissued an "overweight" rating on shares of Sanofi in a report on Wednesday, July 2nd. The Goldman Sachs Group initiated coverage on shares of Sanofi in a report on Friday, March 21st. They set a "neutral" rating and a $65.00 price objective for the company. BNP Paribas initiated coverage on shares of Sanofi in a report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price objective for the company. Finally, Guggenheim reissued a "buy" rating on shares of Sanofi in a report on Tuesday, June 3rd. Three research analysts have rated the stock with a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $61.50.
Read Our Latest Research Report on Sanofi
Sanofi Trading Down 1.5%
Sanofi stock traded down $0.73 during midday trading on Friday, reaching $48.61. The stock had a trading volume of 1,207,445 shares, compared to its average volume of 2,327,496. The company has a quick ratio of 0.69, a current ratio of 1.37 and a debt-to-equity ratio of 0.16. Sanofi has a 52-week low of $45.80 and a 52-week high of $60.12. The firm has a market cap of $119.21 billion, a price-to-earnings ratio of 17.36, a price-to-earnings-growth ratio of 1.12 and a beta of 0.48. The company has a fifty day moving average of $50.05 and a 200 day moving average of $52.08.
Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. Sanofi had a net margin of 14.56% and a return on equity of 17.15%. The company had revenue of $10.41 billion for the quarter, compared to analyst estimates of $9.79 billion. During the same period in the prior year, the company posted $1.78 EPS. The firm's revenue for the quarter was down 11.0% on a year-over-year basis. On average, analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.
Sanofi Increases Dividend
The business also recently announced an annual dividend, which was paid on Thursday, June 12th. Stockholders of record on Friday, May 9th were given a dividend of $2.0369 per share. The ex-dividend date of this dividend was Friday, May 9th. This is a positive change from Sanofi's previous annual dividend of $1.48. This represents a dividend yield of 3.1%. Sanofi's dividend payout ratio (DPR) is 57.14%.
About Sanofi
(
Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Featured Stories
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
